loading...| Preferred Name |
tretinoin |
|
| Synonyms |
Aberel |
|
| Definitions |
A naturally-occurring acid of retinol. Tretinoin binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of tumorigenesis. This agent also inhibits telomerase, resulting in telomere shortening and eventual apoptosis of some tumor cell types. The oral form of tretinoin has teratogenic and embryotoxic properties. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C900" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C900" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000041258 |
|
| altLabel |
Aberel Avita Renova all-trans vitamin A acid Stieva-A trans vitamin A acid (All-E)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid beta-retinoic acid all-trans retinoic acid Vitinoin tretinoinum retinoic acid Retin-A Vesanoid Eudyna Aknoten trans retinoic acid Dermairol TRA Vitamin A Acid Cordes Vas Stieva-A Forte Epi-Aberel Retin-A MICRO Retisol-A Ro 5488 ATRA Airol |
|
| CAS Registry |
302-79-4 |
|
| Component of |
http://purl.bioontology.org/ontology/PDQ/CDR0000042292 http://purl.bioontology.org/ontology/PDQ/CDR0000037972 http://purl.bioontology.org/ontology/PDQ/CDR0000037963 http://purl.bioontology.org/ontology/PDQ/CDR0000041960 http://purl.bioontology.org/ontology/PDQ/CDR0000041636 http://purl.bioontology.org/ontology/PDQ/CDR0000041624 http://purl.bioontology.org/ontology/PDQ/CDR0000041841 http://purl.bioontology.org/ontology/PDQ/CDR0000037970 http://purl.bioontology.org/ontology/PDQ/CDR0000041517 http://purl.bioontology.org/ontology/PDQ/CDR0000041873 http://purl.bioontology.org/ontology/PDQ/CDR0000041470 http://purl.bioontology.org/ontology/PDQ/CDR0000043243 http://purl.bioontology.org/ontology/PDQ/CDR0000410707 http://purl.bioontology.org/ontology/PDQ/CDR0000043293 http://purl.bioontology.org/ontology/PDQ/CDR0000042344 http://purl.bioontology.org/ontology/PDQ/CDR0000042293 http://purl.bioontology.org/ontology/PDQ/CDR0000037962 http://purl.bioontology.org/ontology/PDQ/CDR0000041640 http://purl.bioontology.org/ontology/PDQ/CDR0000043506 http://purl.bioontology.org/ontology/PDQ/CDR0000041945 http://purl.bioontology.org/ontology/PDQ/CDR0000041751 http://purl.bioontology.org/ontology/PDQ/CDR0000037827 http://purl.bioontology.org/ontology/PDQ/CDR0000038090 |
|
| cui |
C1520048 C1520055 C0718748 C0723021 C0595126 C1522491 C1515230 C1520056 C1520050 C1520053 C0593762 C1520049 C1520052 C1520057 C1171295 C1520054 C0040845 C1520051 |
|
| Date last modified |
2010-05-25 |
|
| definition |
A naturally-occurring acid of retinol. Tretinoin binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of tumorigenesis. This agent also inhibits telomerase, resulting in telomere shortening and eventual apoptosis of some tumor cell types. The oral form of tretinoin has teratogenic and embryotoxic properties. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C900" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C900" NCI Thesaurus) |
|
| IND Code |
34987 |
|
| Legacy PDQ ID |
4331 |
|
| LT |
TRD |
|
| NCI ID |
C900 |
|
| notation |
CDR0000041258 |
|
| NSC Code |
122758 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
tretinoin |
|
| tui |
T109 T131 T121 |